Novel drugs and therapeutic targets for severe mood disorders. - Wikidata - wikimedia - TriplyDB

Novel drugs and therapeutic targets for severe mood disorders.

Novel drugs and therapeutic targets for severe mood disorders.

http://www.wikidata.org/entity/Q34732759

about

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development Sigma receptors: potential targets for a new class of antidepressant drug The molecular neurobiology of depression Reproductive Neuroendocrine Pathways of Social Behavior The neurobiology of anhedonia and other reward-related deficits Ketamine for treatment-resistant unipolar depression: current evidence Cell atrophy and loss in depression: reversal by antidepressant treatment Sweet success, bitter defeat: a taste phenotype predicts social status in selectively bred rats A genome-wide association study of neuroticism in a population-based sample Neurotransmitter Systems in a Mild Blast Traumatic Brain Injury Model: Catecholamines and Serotonin.PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3.Antidepressant effect of geranylgeranylacetone in a chronic mild stress model of depression and its possible mechanism Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder.Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats.From synapse to nucleus: novel targets for treating depression.Antidepressant effects of resveratrol in an animal model of depression The association of interoceptive awareness and alexithymia with neurotransmitter concentrations in insula and anterior cingulate Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine.Functional neuroimaging in geriatric depression.NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.Animal models of depression: molecular perspectives.Neurobiological alterations induced by exercise and their impact on depressive disorders [corrected].Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder.Design and fabrication of low-cost 1536-chamber microfluidic microarrays for mood-disorders-related serological studies.Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression Drug development in pediatric psychiatry: current status, future trends.Fetal alcohol spectrum disorders and abnormal neuronal plasticity.Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression?Ketamine for depression: where do we go from here?Neuronal correlates of depression.Is there anything really novel on the antidepressant horizon?Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis Neurobiological mechanisms in major depressive disorder Target identification for CNS diseases by transcriptional profiling.Molecular imaging as a guide for the treatment of central nervous system disorders

P2860

Q21129334-904700DB-CE86-48F7-AA89-F1C9099A325E Q22241837-35C78D8F-DA71-4212-ABDA-32C4D8495237 Q24567770-EABD9ABD-DD9C-4B2C-B3A3-A594B7D98D5C Q24656261-D6B734F1-3A59-4B5E-BC6F-6E255A4C067C Q26749620-DB755D19-0B78-4E82-B505-20BEFCDC9E2B Q26853518-404C9F42-B0FC-47F9-A98B-90AD9F4C6B3C Q27004508-FD081B81-6354-4B32-B90A-9FD8611D30EF Q27013609-3C0ADE40-0702-4F58-B09D-A63F8A464033 Q27316028-26819891-3729-4EB7-8D22-8B0F20B9A8B3 Q28750404-20E80F31-9400-4C47-8004-CAABA170FB03 Q30376522-D7AD35C1-43F7-4497-BE6F-1F6896D671C6 Q30447840-44D7941A-C30A-4F20-A6FE-3C69269A9C3C Q30448619-8B35F83C-9100-4745-A9F5-0DA2777A63FF Q33389974-E48FA386-9CE9-4D34-949E-236C6A959362 Q33624583-93B76BFF-6B37-410C-8FE5-9F94780768DE Q33653177-38AB66F4-1894-43A1-9B75-98933A44D4A3 Q33663230-9229A37C-C4FB-4990-991C-DD24DB826D52 Q33692296-A32D50F6-ED7B-4918-A089-0F2331002EF4 Q33783427-44901389-F3B0-4A3B-A887-9592599D3F78 Q33848833-CC533550-5D03-4BE4-9409-25D5937BA1D7 Q33887659-F480C10C-E2CD-4270-885D-A312DDCA0B64 Q34050607-DA64D219-586E-4717-9452-34160B72C15C Q34157073-061BA2DD-CD3E-4863-8AD6-34AE04CEA358 Q34158534-5B7B3AA1-B433-4066-98EF-B0AD6D9A3FDE Q34517902-42E54859-2212-4251-9ADD-E459419013AE Q34548121-F2B05506-0F00-45FA-A060-37D25CA50869 Q35028320-C49570D0-0F55-4447-9BFF-5135325103DF Q35577677-E4C0D3FF-20D6-4EA6-99AE-3FACAA589BCF Q35737324-74F40E53-65D2-4EAF-9F72-2D4E12EAA58E Q35811894-1691A53C-EB6C-44EB-A1E5-53F23A706B65 Q35915502-61B806BF-D6E1-4314-ADFC-F68F9B4C4AEA Q36007530-65A2CFA2-4AF9-49BE-A814-226B0B9C31C1 Q36067322-DACABFFF-93A1-478E-9E54-E19400E63EC7 Q36223372-0E7098BA-46B3-4FB7-942E-6B7EA25D4107 Q36451816-04461CA9-222E-481B-ACC6-313BE461D983 Q36870889-6CF3D7AC-B34E-48E6-B290-4757A6B16CEC Q36982911-B648CDB9-920E-45CC-AF1D-B72B53A93D3D Q37071342-ECD9D8AB-09E4-42EF-AE0A-89FCA5E5C86E Q37175279-1AA78C02-9525-4CFB-B26F-296A206AD3AB Q37262953-C2E831EC-4002-4EB7-85BA-0AF96126AE7B

P2860

Novel drugs and therapeutic targets for severe mood disorders.

http://www.wikidata.org/entity/Q34732759

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Novel drugs and therapeutic targets for severe mood disorders.

@ast

Novel drugs and therapeutic targets for severe mood disorders.

@en

Novel drugs and therapeutic targets for severe mood disorders.

@nl

type

label

Novel drugs and therapeutic targets for severe mood disorders.

@ast

Novel drugs and therapeutic targets for severe mood disorders.

@en

Novel drugs and therapeutic targets for severe mood disorders.

@nl

prefLabel

Novel drugs and therapeutic targets for severe mood disorders.

@ast

Novel drugs and therapeutic targets for severe mood disorders.

@en

Novel drugs and therapeutic targets for severe mood disorders.

@nl

P1433

Q34732759-4BE9033F-CE16-435C-AB60-20436F8DB22A

P1476

Q34732759-810EBC92-7823-4A12-95C8-3EC2FD651407

P2093

Q34732759-00735F97-71E4-4379-835F-31DDC02EC273

Q34732759-143613B1-4FCF-453B-BF22-5089DED9A740

Q34732759-19D08E63-D4B9-4D00-94DE-2ECEAE70BCC9

P2860

Q34732759-06519A1C-057A-4293-AEB0-3112C6515FE4

Q34732759-08168151-0B15-4B72-A01E-C1928A60E04C

Q34732759-0ABA17C8-D5F9-46FF-959C-C9CA8C9E6CBF

Q34732759-0B0D5423-5EF7-4271-8537-1941ED6D9B73

Q34732759-0B736E89-89FB-439B-AA9E-DB7A91B278FA

Q34732759-0BEEE290-9E25-4ED2-8A10-4FB09F39A43E

Q34732759-0DD9B56A-30E1-4B28-86E6-88CE79B074DF

Q34732759-0E0C607C-8D10-4116-98BF-BB61D5B11EF8

Q34732759-0E0CFA70-36C8-44C6-997F-2957B3467A01

Q34732759-0E53FA59-9404-44CD-A195-4A3B0B92929E

P2888

Q34732759-8591C69F-9B04-4AE8-BD34-D1FF40EEB722

P304

Q34732759-750C00E0-A41A-4436-BAB0-98112F5FAE09

P31

Q34732759-CFE3FABF-4BF1-4C1D-B842-5D3B2BBECFD9

P356

Q34732759-6E5BECEF-D04A-4991-92F1-831F5C42F0AB

P407

Q34732759-B0F2F1E9-20BE-4825-8A71-F5048582C126

P433

Q34732759-EE4FE19A-8F4C-475E-B6AD-4C701839B5B3

P478

Q34732759-4E230156-1186-4A9F-96F6-2BCEF6A92F51

P577

Q34732759-AB137CDC-6187-4041-88CA-BBCB6E8AD3A2

P6179

Q34732759-62E85A2D-809A-4A50-A5F1-4BEB89760FD3

P698

Q34732759-28ED67AE-DD80-4DF0-AB73-E91553481933

P356

P1433

Neuropsychopharmacology

P1476

Novel drugs and therapeutic targets for severe mood disorders.

@en

P2093

Dennis S Charney

http://www.w3.org/2001/XMLSchema#string

Husseini K Manji

http://www.w3.org/2001/XMLSchema#string

Sanjay J Mathew

http://www.w3.org/2001/XMLSchema#string

P2860

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

GSK-3: tricks of the trade for a multi-tasking kinase

A molecular mechanism for the effect of lithium on development

Circadian genes, rhythms and the biology of mood disorders

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

P2888

P304

2080-2092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1301652

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1044235174

http://www.w3.org/2001/XMLSchema#string

P698

18172433

http://www.w3.org/2001/XMLSchema#string